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Background: According to the Joint ESC/ACC/AHA/WHF Task Force, Tn is the preferred biomarker for the diagnosis of acute MI. However, it is still 
common practice to order both serial CKMB and Tn to rule out acute MI. Our hypothesis is that most clinicians only use Tn and not CKMB in further 
management decisions when both test results are available.
Methods: At our large regional academic medical center 65,950 patients who presented to the Emergency Department(ED) during a 5 year 
period(01/01/05 to 12/31/2010) had a Tn within 4 hours of arrival and at least 2 sets of Tn and CKMB within 24 hours. Of these, 9605 patients 
were admitted to our Clinical Decision Unit, with the express purpose of ruling out acute MI. These patients were then divided into Group 1 ( 9204 
patients- normal serial Tn and CKMB) : mean age 57.33 years, males 45.22%, Caucasian 72.11%, African-American 22.38% and Group 2 (401 
patients- normal serial Tn and elevated CKMB ): mean age 58.33 years, males 72.82%, Caucasian 67.58%, African- American 27.43%.
Results: Our results show that there was no statistically significant difference between the two groups in further testing and disposition pathways 
based on CKMB results(See Table)
Conclusions: vIn our patient population, elevated CKMB in the absence of elevated troponin did not influence further management decisions. 
CKMB is reimbursed by Medicare at $9.17 per test. With 6 million ED visits per year for chest pain this amounts to saving hundreds millions of 
dollars in health care expenditure.
 
